Callitas Health Inc. Aktie Canadian Securities Exchange
Aktien
A2GSU1
CA13125C1068
LILY
Biotechnologie
Umsatz 2018 | 0.75 1.02 0.68 | Umsatz 2019 | 0.71 0.97 0.64 | Marktwert | 3.53 Mio. 4.81 Mio. 3.21 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2018 | -5 Mio. -6.81 Mio. -4.55 Mio. | Nettoergebnis 2019 | -1 Mio. -1.36 Mio. -909’420 | EV / Sales 2018 | 4’852’616 x |
Nettoschuld 2018 | 318’990 434’767 290’096 | Nettoschuld 2019 | 847’693 1.16 Mio. 770’909 | EV / Sales 2019 | 6’168’166 x |
KGV 2018 |
-0.6
x | KGV 2019 |
-1.97
x | Beschäftigte | - |
Rendite 2018 * |
-
| Rendite 2019 |
-
| Streubesitz | 72.04% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | - | 03.01.18 | |
Robert Payment
DFI | Director of Finance/CFO | 42 | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Donald Skeith
BRD | Director/Board Member | 69 | 01.12.14 |
William Rodgers
BRD | Director/Board Member | - | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
% 1. Jan. | Kap. | |
---|---|---|
+41.79% | 54.04 Mrd. | |
-0.56% | 41.92 Mrd. | |
+47.30% | 41.96 Mrd. | |
-7.20% | 28.35 Mrd. | |
+12.59% | 26.35 Mrd. | |
-21.51% | 19 Mrd. | |
+6.92% | 13 Mrd. | |
+24.91% | 12.19 Mrd. | |
+29.60% | 12.28 Mrd. |